Phase III
Danish company Novo Nordisk is reportedly considering cost-cutting plans that would cut up to 3,000 jobs.
There are generally two types of antidepressants on the market. They are selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). But there are still individuals who do not respond well to these drugs and the industry continues to work on developing better and alternative treatments for depression.
Biogen signed an exclusive option deal with Tokyo-based TMS for TMS-007 and backup compounds.
Hookipa Biotech and Gilead inked a research collaboration deal to develop and commercialize therapeutics for hepatitis B (HBV) and HIV.
Tricida, a late-stage biotech company developing therapies for conditions associated with chronic kidney disease (CKD), filed late Monday with the Securities and Exchange Commission to raise up to $150 million in an initial public offering.
AbbVie announced positive topline results from its SELECT-EARLY Phase III clinical trial in rheumatoid arthritis, but disappointed with Rova-T small-cell lung cancer therapy.
Horizon Pharma and the National Organization for Rare Disorders (NORD) launched a new campaign today that recognizes innovation in rare disease therapeutics since the passing of the Orphan Drug Act in 1983.
BioSpace takes a look at some notable programs that have been shuttered so far this year.
There’s plenty of news coming out of the American Society of Clinical Oncology (ASCO) Annual Meeting behind held in Chicago. Here’s a look at a few more of the top stories.
The Janssen Pharmaceutical Companies, part of Johnson & Johnson, presented two-year data from its IM-UNITI trial of Stelara (ustekinumab) in Crohn’s disease.
PRESS RELEASES